Prosecution Insights
Last updated: November 12, 2026
Application No. 17/997,463

IRAK INHIBITORS AND USES THEREOF

Final Rejection §112
Filed
Oct 28, 2022
Priority
Apr 28, 2020 — provisional 63/016,387 +1 more
Examiner
YOO, SUN JAE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kymera Therapeutics Inc.
OA Round
3 (Final)
71%
Grant Probability
Favorable
4-5
OA Rounds
72%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
886 granted / 1250 resolved
+10.9% vs TC avg
Minimal +1% lift
Without
With
+1.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
93 currently pending
Career history
1321
Total Applications
across all art units

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement 2. The information disclosure statement (IDS) submitted on September 17, 2026 was in compliance with the provisions of 37 CFR 1.97 and 37 CFR 1.98. The IDS was considered. A signed copy of form 1449 is enclosed herewith. Response to Amendment 3. The amendments to the claims filed on September 17, 2026 have been fully considered. The amendments are sufficient to overcome the 35 USC 102 rejection over WO 2017009806 which is withdrawn. 4. The amendments are not sufficient to overcome the outstanding Improper Markush rejection or objection of claim 17. Below are responses to Applicant’s remarks. Claim 17 was previously objected to for depending on a base rejected claim. This objection is maintained because the independent claim remains rejected. The claims were previously rejected on the basis that they contain improper Markush grouping of alternatives. The Markush grouping was improper because the alternative defined do not share a single structural similarity and common use due to the variable ring structures in the core afforded by A, B and C. Applicants have amended the claims to recite A is benzo. However, rings B and C are still generically defined to contain variable core structures due to these variables Applicants state that a substantial core structure exists due to benzothiazole This argument is not found to be persuasive as the benzothiazole is only part of the core which is further defined by variables B and C. For the reasons stated, the Improper Markush rejection is maintained. Claims 1, 2, 7-9, 12, 14-16 and 18 remain rejected. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE YOO whose telephone number is (571)272-9074. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUN JAE YOO/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Oct 28, 2022
Application Filed
Oct 27, 2025
Non-Final Rejection mailed — §112
Jan 29, 2026
Response Filed
May 21, 2026
Non-Final Rejection mailed — §112
Sep 17, 2026
Response Filed
Oct 16, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780779
CXCR6 SULFONAMIDE COMPOUNDS
3y 7m to grant Granted Nov 03, 2026
Patent 12780778
CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF
3y 3m to grant Granted Nov 03, 2026
Patent 12780795
CRYSTALLINE FORM OF TRICYCLIC DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
2y 11m to grant Granted Nov 03, 2026
Patent 12778121
ACRYLATE DERIVATIVE, USE AND PRODUCTION INTERMEDIATE COMPOUND OF THE SAME
2y 3m to grant Granted Nov 03, 2026
Patent 12767631
METHOD FOR PRODUCING POLYETHER NITRILE
2y 5m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
71%
Grant Probability
72%
With Interview (+1.0%)
High
PTA Risk
Based on 1250 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month